Skip to Content

A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Phase II Clinical Trial

Indication: Melanoma
Trial Number: 03897881
Trial Status: OPEN

Participating Locations